Main Article Content
Aim of the investigation — to study serum levels of apolipoprotein A1 and B and their ratio in 174 young adults (average age — 22.47 ± 0.30 years) with childhood-onset growth hormone deficiency. Materials and methods. The study involved 174 patients (124 males) aged 19 to 34 years. The follow-up period was up to 36 months. Results. It was found that on the background of the treatment with recombinant growth hormone (rGR), there is a gradual increase in the levels of apolipoprotein A1, a decrease in apolipoprotein B levels and normalization of their ratio in most patients after 6–12 months that reduces cardiovascular risk factors in the future. Conclusions. Against the background of rGR therapy in young adults with childhood-onset growth hormone deficiency, there are significant positive changes in some parameters of the lipid profile, namely — substantial increase in apolipoprotein A1 levels, a decrease in the serum content of apolipoprotein B and apoB/apoA1 ratio.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Zak T., Basiak A., Zubkiewicz-Kucharska A., Noczyńska A. The effect of one year therapy with recombinant human growth hormone (rhGH) on growth velocity, calcium-phosphorus metabolism, bone mineral density and changes in body composition in children with growth hormone deficiency (GHD) // Pediatr. Endocrinol. Diabetes Metab. — 2010. — Vol. 16(1). — P. 39-43.
Verhelst J., Abs R. Cardiovascular risk factors in hypopituitary GH-deficient adults // Eur. J. Endocrinol. — 2009. — Vol. 161. — P. 41-49. — doi: 10.1530/EJE‑09-0291.
Karavia E.A., Zvintzou E., Petropoulou P.I. et al. HDL quality and functionality: what can proteins and genes predict? // Expert Rev. Cardiovasc. Ther. — 2014. — Vol. 12(4). — P. 521-532. — doi: 10.1586/14779072.2014.896741.
Russell-Jones D.L., Watts G.F., Weissberger A. et al. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients // Clin. Endocrinol. (Oxf.). — 1994. — Vol. 41(3). — P. 345-350.
Claessen K.M., Appelman-Dijkstra N.M., Adoptie D.M. et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy // J. Clin. Endocrinol. Metab. — 2012. — Nov 15 [Epub ahead of print].
Dominiczak M.H., Caslake M.J. Apolipoproteins: metabolic role and clinical biochemistry applications // Ann. Clin. Biochem. — 2011. — Vol. 48. — P. 498-515. — doi: 10.1258/acb.2011.011111.
Wu J.F., Tang Y.Y., Zeng G.F., Tang C.K. Role of apolipoprotein AI on nascent high-density lipoprotein particle formation // Sheng Li Ke Xue Jin Zhan. — 2014. — Vol. 45(2). — P. 81-86.
Feldt-Rasmussen U., Wilton P., Jonsson P., KIMS Study Group; KIMS International Board. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults // Growth Horm. IGF Res. — 2004. — Vol. 14. — P. 51-58.
Gasco V., Prodam F., Grottoli S. et al. Growth hormone therapy in adult growth hormone deficiency: a review of treatment schedules and the evidence for low starting doses // Eur. J. Endocrinol. — 2012. — Nov 14 [Epub ahead of print].
Kokshoorn N.E., Biermasz N.R., Roelfsema F. et al. GH replacement therapy in elderly GH-deficient patients: a systematic review // Eur. J. Endocrinol. — 2011. — Vol. 164(5). — P. 657-665.
Johannsson G.J. What happens when growth hormoneis discontinue dat completion of growth? Metabolic aspects // J. Pediatr. Endocrinol. Metab. — 2000. — Vol. 13. — P. 1321-1326.
Lanes R., Soros A., Gunczler P. et al. Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipid and lipoproteins // J. Pediatr. — 2011. — Vol. 149. — P. 324-329.
Sahebkar A., Watts G.F. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes // Clin. Ther. — 2013. — Vol. 35(8). — P. 1082-1098. — doi: 10.1016/j.clinthera.2013.06.019.
Tuteja S., Rader D.J. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm // Clin. Pharmacol. Ther. — 2014. — Vol. 96(1). — P. 48-56. — doi: 10.1038/clpt.2014.79.
Kołtowska-Häggström M., Geffner M.E., Jönsson P. et al. Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with non idiopathic childhood-onset GH deficiency // J. Clin. Endocrinol. Metab. — 2010. — Vol. 95(6). — P. 2646-2654.
Ahmid M., Fisher V., Graveling A.J. et al. Аn audit of the management of childhood-onset growth hormone deficiency during young adulthood in Scotland // Int. J. Pediatr. Endocrinol. — 2016. — Vol. 6.
Sukhanov S., Snarski P., Vaughn C. et al. Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase // Atherosclerosis. — 2015. — Vol. 238(2). — P. 313-320. — doi: 10.1016/j.atherosclerosis.2014.12.024.
Panayiotou A., Griffin M., Georgiou N. et al. ApoB/ApoA1 ratio and subclinical atherosclerosis // Int. Angiol. — 2008. — Vol. 27(1). — P. 74-80.